Imfinzi passes first step to reimb in KOR… key is the price
By Whang, byung-woo | translator Alice Kang
24.11.19 05:14:22
가나다라
0
Imfinzi has set reimb standards as a first-line treatment for biliary tract cancer after failing to establish standards last year
AZ proposes a new plan regarding the drug’s price… data on Koreans positively affect the reimb decision
Cost burden hurdle remains...how its expanded scope of use in biliary tract and liver cancer will affect the government's decision gains attention
With the reimbursement standard set for the immuno-oncology drug Imfinzi (durvalumab), which is under review for reimbursement extensions, how the discussions will develop thereafter is gaining attention.
Although the first step has been taken, attention is being paid to the future process as the matter was mentioned during the National Assembly’s Health Insurance Review and Assessment Service National Audit.
The drug price is the key issue. Consensus on the cost is expected to be crucial amid the rising health insurance expenses being spent on anticancer drugs.
▲Pic of Imfinzi
According to industry sources on the 18th, the Health Insurance Review and Assessment Service recently held the
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)